Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study
BACKGROUND: We evaluated the predictive ability of cystatin C and creatinine-based estimations of glomerular filtration rate (eGFR), including the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, in acute coronary syndrome (ACS) patients with (STE-ACS) or without (NSTE-ACS) ST elevation in a...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Clinical chemistry
Year: 2012, Jahrgang: 58, Heft: 1, Pages: 190-199 |
| ISSN: | 1530-8561 |
| DOI: | 10.1373/clinchem.2011.171520 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1373/clinchem.2011.171520
|
| Verfasserangaben: | Åxel Akerblom, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Kristen Buck, Evangelos Giannitsis, Jay Horrow, Steen Husted, Hugo A. Katus, Philippe Gabriel Steg, Robert F. Storey, Nils Åsenblad, Stefan K. James |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1571806857 | ||
| 003 | DE-627 | ||
| 005 | 20230426124234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180409s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1373/clinchem.2011.171520 |2 doi | |
| 035 | |a (DE-627)1571806857 | ||
| 035 | |a (DE-576)501806857 | ||
| 035 | |a (DE-599)BSZ501806857 | ||
| 035 | |a (OCoLC)1341001897 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Åkerblom, Axel |e VerfasserIn |0 (DE-588)1155729072 |0 (DE-627)1017929858 |0 (DE-576)501809953 |4 aut | |
| 245 | 1 | 0 | |a Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes |b results from the Platelet Inhibition and Patient Outcomes study |c Åxel Akerblom, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Kristen Buck, Evangelos Giannitsis, Jay Horrow, Steen Husted, Hugo A. Katus, Philippe Gabriel Steg, Robert F. Storey, Nils Åsenblad, Stefan K. James |
| 264 | 1 | |c 2012 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.04.2018 | ||
| 520 | |a BACKGROUND: We evaluated the predictive ability of cystatin C and creatinine-based estimations of glomerular filtration rate (eGFR), including the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, in acute coronary syndrome (ACS) patients with (STE-ACS) or without (NSTE-ACS) ST elevation in a large contemporary ACS population. METHODS: Concentrations of cystatin C and creatinine, as well as eGFR at randomization, were measured in 16 401 patients in the Platelet Inhibition and Patient Outcomes (PLATO) study and evaluated as predictors of the composite end point of cardiovascular death or myocardial infarction within 1 year. Two Cox proportional hazards models were used, the first adjusting for clinical characteristics and the second for clinical characteristics plus the biomarkers N-terminal pro-B-type natriuretic peptide, troponin I, and C-reactive protein. RESULTS: The median cystatin C value was 0.83 mg/L. Increasing quartiles of cystatin C were strongly associated with poor outcome (6.9%, 7.1%, 9.5%, and 16.2%). The fully adjusted hazard ratios per SD of cystatin C in the NSTE-ACS and STE-ACS populations were 1.12 (95% CI 1.04-1.20) (n=8053) and 1.06 (95% CI 0.97-1.17) (n=5278), respectively. There was no significant relationship of cystatin C with type of ACS (STE or NSTE). c Statistics ranged from 0.6923 (cystatin C) to 0.6941 (CKD-EPI). CONCLUSIONS: Cystatin C concentration contributes independently in predicting the risk of cardiovascular death or myocardial infarction in NSTE-ACS, with no interaction by type of ACS. CKD-EPI exhibited the largest predictive value of all renal markers. Nevertheless, the additive predictive value of cystatin C or creatinine-based eGFR measures in the unselected ACS patient is small. | ||
| 650 | 4 | |a Acute Coronary Syndrome | |
| 650 | 4 | |a Adenosine | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a C-Reactive Protein | |
| 650 | 4 | |a Creatinine | |
| 650 | 4 | |a Cystatin C | |
| 650 | 4 | |a Double-Blind Method | |
| 650 | 4 | |a Endpoint Determination | |
| 650 | 4 | |a Glomerular Filtration Rate | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Myocardial Infarction | |
| 650 | 4 | |a Natriuretic Peptide, Brain | |
| 650 | 4 | |a Peptide Fragments | |
| 650 | 4 | |a Platelet Aggregation Inhibitors | |
| 650 | 4 | |a Proportional Hazards Models | |
| 650 | 4 | |a Protein Precursors | |
| 650 | 4 | |a Ticlopidine | |
| 650 | 4 | |a Troponin I | |
| 700 | 1 | |a Giannitsis, Evangelos |e VerfasserIn |0 (DE-588)113336241 |0 (DE-627)577184091 |0 (DE-576)289759579 |4 aut | |
| 700 | 1 | |a Katus, Hugo |d 1951- |e VerfasserIn |0 (DE-588)108916618 |0 (DE-627)577155040 |0 (DE-576)289625076 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry |d Washington, DC : American Association for Clinical Chemistry, 1955 |g 58(2012), 1, Seite 190-199 |h Online-Ressource |w (DE-627)266883117 |w (DE-600)1468161-4 |w (DE-576)075146401 |x 1530-8561 |7 nnas |a Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes results from the Platelet Inhibition and Patient Outcomes study |
| 773 | 1 | 8 | |g volume:58 |g year:2012 |g number:1 |g pages:190-199 |g extent:10 |a Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes results from the Platelet Inhibition and Patient Outcomes study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1373/clinchem.2011.171520 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180409 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 108916618 |a Katus, Hugo |m 108916618:Katus, Hugo |d 910000 |d 910100 |e 910000PK108916618 |e 910100PK108916618 |k 0/910000/ |k 1/910000/910100/ |p 10 | ||
| 998 | |g 113336241 |a Giannitsis, Evangelos |m 113336241:Giannitsis, Evangelos |d 910000 |d 910100 |e 910000PG113336241 |e 910100PG113336241 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 999 | |a KXP-PPN1571806857 |e 3005338800 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"2012","dateIssuedKey":"2012"}],"relHost":[{"title":[{"subtitle":"journal of the American Association for Clinical Chemistry ; international journal of laboratory medicine and molecular diagnostics","title":"Clinical chemistry","title_sort":"Clinical chemistry"}],"id":{"zdb":["1468161-4"],"eki":["266883117"],"issn":["1530-8561"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Washington, DC ; Oxford","dateIssuedKey":"1955","dateIssuedDisp":"1955-","publisher":"American Association for Clinical Chemistry ; Oxford University Press"}],"recId":"266883117","corporate":[{"display":"American Association of Clinical Chemists","role":"isb"}],"disp":"Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes results from the Platelet Inhibition and Patient Outcomes studyClinical chemistry","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"part":{"issue":"1","pages":"190-199","extent":"10","text":"58(2012), 1, Seite 190-199","volume":"58","year":"2012"},"note":["Gesehen am 26.08.2021"],"pubHistory":["1.1955 -"]}],"id":{"eki":["1571806857"],"doi":["10.1373/clinchem.2011.171520"]},"physDesc":[{"extent":"10 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes","title":"Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes","subtitle":"results from the Platelet Inhibition and Patient Outcomes study"}],"note":["Gesehen am 09.04.2018"],"person":[{"display":"Åkerblom, Axel","given":"Axel","role":"aut","family":"Åkerblom"},{"given":"Evangelos","display":"Giannitsis, Evangelos","role":"aut","family":"Giannitsis"},{"role":"aut","family":"Katus","display":"Katus, Hugo","given":"Hugo"}],"recId":"1571806857","name":{"displayForm":["Åxel Akerblom, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Kristen Buck, Evangelos Giannitsis, Jay Horrow, Steen Husted, Hugo A. Katus, Philippe Gabriel Steg, Robert F. Storey, Nils Åsenblad, Stefan K. James"]},"language":["eng"]} | ||
| SRT | |a AKERBLOMAXCYSTATINCA2012 | ||